ClinicalTrials.gg
Not yet recruitingNCT07401849BEAD-PCUpdated Feb 11, 2026

Blood Biomarkers for Early and Accurate Diagnosis of Alzheimer's Disease in Primary Care

An observational study in Alzheimer Disease, Biomarkers / Blood and Biomarker in Early Diagnosis, sponsored by Imperial College London. Not yet recruiting. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-02-11.

Sponsored by Imperial College London · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Ecologic or community
Time perspective
Prospective
Enrollment
1,000
Ages
55 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Alzheimer Disease by Imperial College London — 6 open to participants now, 7 under way, 1 of them phase 3. Alzheimer Disease · Imperial College London.

Started
2026
the only one that year
Observational
3 of 11
3 open now
Registered
11th of 11
by date

Among the 11 studies in Alzheimer Disease by Imperial College London, this one is the only one that started in 2026, is one of 3 observational ones, and was the 11th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

6 of the 11 studies in Alzheimer Disease by Imperial College London are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 55 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Alzheimer Disease by Imperial College London, or all of them as a file.
02

Study summary

Alzheimer's disease is a degenerative condition affecting the brain and is the most common form of dementia in older adults. Dementia is currently a major healthcare issue in the UK, affecting approximately a million people. The progression of the disease varies between individuals and the early stages may be characterised by only minimal changes in memory and thinking. These changes could remain undetected as the symptoms may be mistakenly regarded as normal age-related forgetfulness. However, dementia is not part of the normal ageing process.

The underlying biological disease process of Alzheimer's is now known to start at least 20 years prior to patients showing any symptoms. A protein called amyloid starts to deposit in the brain and forms clumps referred to as 'plaques'. Another protein called tau collects inside brain cells and forms structures called 'tangles'. These biological changes can disrupt the normal functioning of brain cells and ultimately destroy them, leading to a reduction in brain volume and ability.

The aim of the BEAD-PC study is to assess whether a specific blood test in primary care can help diagnose Alzheimer's disease at an early stage.

03

Conditions studied

  • Alzheimer Disease
  • Biomarkers / Blood
  • Biomarker in Early Diagnosis
  • Mild Cognitive Impairment (MCI)

Keywords

  • Alzheimer's Disease
  • Memory complaints
  • Mild Cognitive Impairment
  • Primary care
  • Blood biomarkers
  • Neuropsychological assessment
04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Eligible patients from 124 GP surgeries England.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 55 years and above
  • Presence of self-reported symptoms indicative of cognitive decline or concerns family members/partners indicative of cognitive decline
  • Capacity to consent
  • Be fluent in and able to read and write in English and have adequate hearing and visual acuity to complete the required psychometric tests.

Exclusion criteria

Exclusion Criteria:

  • Insufficient vision and hearing
  • Prior diagnosis of ADRD. Prior diagnosis of Alzheimer's disease or related dementia (with or without evidence of pathology), through clinical diagnosis and/or as documented in their medical record
  • Pre-existing diagnosis of dementia
  • Incidental findings of brain pathologies on brain MRI, such as cancerous space occupying lesions and vascular malformations and recent (within 12 months) macro-infarcts, that are, also exclusionary
  • for Lumbar Puncture
  • Involvement in interventional research study within 3 months prior to screening
  • For any other reason, in the opinion of the Investigator, participating in the study is not in the best interest of the patient.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Ecologic or community
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Presence of Alzheimer-specific blood biomarkers

    Amyloid and Tau protein biomarkers identified in blood sample

    Time frame: Day 1 (study entry)

  2. Presence of Alzheimer-specific Cerebrospinal Fluid (CSF) biomarkers

    Amyloid and Tau protein biomarkers found in CSF

    Time frame: Follow-up visit (around 6 months after study entry)

Secondary outcomes

  1. Montreal Cognitive Assessment (MoCA) score

    Pen-and-paper cognitive test commonly used to identify Mild Cognitive Impairment (MCI) in older adults.

    Time frame: Day 1 (study entry)

  2. CANTAB score

    Online, self-completed battery of cognitive tests validated for detecting signs of AD-related cognitive decline.

    Time frame: Day 1 (study entry)

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Feb 2026; primary completion for Nov 2026, 9 months later.

Of 364 non-industry observational studies under Alzheimer Disease, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 203. This study's planned 9 months is below that.

Counting every sponsor, half of 405 studies reached it within 67 months; a quarter within 35 and three quarters within 171.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2026
First posted
Feb 11, 2026
StartEst.
Feb 2026
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2026
Last update
Feb 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07401849
Responsible party
Sponsor
First posted
Feb 11, 2026
Start date
Feb 2026 (estimated)
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Feb 11, 2026

Study contacts

Project Manager
Contact
beadpc@imperial.ac.uk
+44 20 7594 3894
Lefkos Middleton, Prof
study chair · Imperial College London
David Wingfield, Dr
principal investigator · Imperial College London

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion